Takeda Outlicenses Two CCR5 Antagonists To Newly Formed Tobira
This article was originally published in The Pink Sheet Daily
Executive Summary
TAK-652’s potential for once-daily dosing could make it the best-in-class oral CCR5 antagonist, Tobira’s CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
Takeda, Santhera Extend Partnership On Idebenone To Duchenne Muscular Dystrophy
Takeda and the Swiss specialty pharma Santhera Pharmaceuticals are extending an existing collaboration on SNT-MC17 (idebenone) for the neuromuscular disease Friedreich's Ataxia to include a second indication for Duchenne muscular dystrophy, the firms announced Aug. 2
Takeda, Santhera Extend Partnership On Idebenone To Duchenne Muscular Dystrophy
Takeda and the Swiss specialty pharma Santhera Pharmaceuticals are extending an existing collaboration on SNT-MC17 (idebenone) for the neuromuscular disease Friedreich's Ataxia to include a second indication for Duchenne muscular dystrophy, the firms announced Aug. 2
Schering-Plough, Incyte Report Positive Mid-Stage Data For CCR5 Antagonists
Both Schering’s vicriviroc and Incyte’s INCB9471 CCR5 antagonist candidates to treat HIV beat placebo in Phase II trials.